PFA
TMO icon

Pathway Financial Advisers’s Thermo Fisher Scientific TMO Stock Holding History

Pathway Financial Advisers’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$795K Buy
1,587
+84
+6% +$40.3K 0.2% 115
2026
Q1 		$739K Sell
1,503
-101
-6% -$54.8K 0.21% 112
2025
Q4 		$929K Sell
1,604
-39
-2% -$22.1K 0.27% 102
2025
Q3 		$781K Buy
1,643
+151
+10% +$70.3K 0.23% 106
2025
Q2 		$605K Buy
1,492
+107
+8% +$44.7K 0.2% 116
2025
Q1 		$689K Buy
1,385
+55
+4% +$29.8K 0.24% 106
2024
Q4 		$692K Sell
1,330
-93
-7% -$51.1K 0.23% 110
2024
Q3 		$880K Sell
1,423
-27
-2% -$16K 0.4% 73
2024
Q2 		$783K Buy
1,450
+33
+2% +$18.9K 0.28% 103
2024
Q1 		$824K Sell
1,417
-284
-17% -$159K 0.3% 98
2023
Q4 		$903K Buy
1,701
+4
+0.2% +$1.94K 0.34% 86
2023
Q3 		$861K Buy
+1,697
New +$904K 0.36% 82
2023
Q1 		$966K Sell
1,675
-1
-0.1% -$564 0.39% 78
2022
Q4 		$923K Buy
+1,676
New +$888K 0.37% 78

Other funds holding TMO

Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LT
Lindsell Train London, United Kingdom $2.63B AUM 2.97% 1-Year Est. Return

Pathway Financial Advisers's TMO Position: Q2 2026 in Review

Pathway Financial Advisers increased its Thermo Fisher Scientific (TMO) stake by 5.6% in Q2 2026, buying an estimated $40.3K and bringing the position to 1,587 shares worth $795K. The position accounts for 0.2% of the portfolio, ranked #115.

Pathway Financial Advisers first reported a position in TMO in Q4 2022 and has held it in 14 quarters since. The position peaked at $966K in Q1 2023. 1,172 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Pathway Financial Advisers held 1,587 shares of Thermo Fisher Scientific worth $795K as of Q2 2026.
  • Pathway Financial Advisers bought 84 Thermo Fisher Scientific shares in Q2 2026, an estimated $40.3K.
  • Thermo Fisher Scientific made up 0.2% of Pathway Financial Advisers's portfolio in Q2 2026, its #115 holding.
  • Pathway Financial Advisers first reported a position in Thermo Fisher Scientific in Q4 2022 and has held it in 14 quarters since.
  • Pathway Financial Advisers's Thermo Fisher Scientific position peaked at $966K in Q1 2023.
  • 1,172 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Pathway Financial Advisers's 13F filing for Q2 2026, filed 30 Jul 2026.